Abstract
This chapter will provide a comprehensive overview of both primary and secondary haemostasis at a gross and molecular level, in addition to examining the relevant signalling and cellular mediators of these dual processes. We will then discuss three key regulatory mechanisms, whilst simultaneously exploring the clinical relevance of both the aforementioned mechanisms and the aberrance of coagulation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Versteeg HH et al (2013) New fundamentals in hemostasis. Physiol Rev 93:327. https://www.physiology.org/doi/full/10.1152/physrev.00016.2011
Broos K et al (2011) Platelets at work in primary hemostasis. Blood Rev 25(4):155–167. https://doi.org/10.1016/j.blre.2011.03.002
Peyvandi F et al (2011) Role of von Willebrand factor in the haemostasis. Blood Transfus 9(Suppl 2):s3–s8. https://doi.org/10.2450/2011.002S
Gale AJ (2011) Current understanding of hemostasis. Toxicol Pathol 39(1):273–280. https://doi.org/10.1177/0192623310389474
Seong-Hoon Y et al (2016) Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int 2016:1. https://doi.org/10.1155/2016/9060143
Blair P et al (2009) Platelet a-granules: basic biology and clinical correlates. Blood Rev 23(4):177–189. https://doi.org/10.1016/j.blre.2009.04.001
Hanby HA et al (2017) Platelet dense granules begin to selectively accumulate mepacrine during proplatelet formation. Blood Adv 1(19):1478–1490. https://doi.org/10.1182/bloodadvances.2017006726
Behan MWH, Storey RF (2004) Antiplatelet therapy in cardiovascular disease. Postgrad Med J 80:155–164. https://doi.org/10.1136/pgmj.2003
Bhatt DL, Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2(1):15–29. https://doi.org/10.1038/nrd985
Savi P et al (1998) Clopidogrel: a review of its mechanism of action. Platelets 9(3–4):251–255. https://doi.org/10.1080/09537109876799
Chatterjee S et al (2013) PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis 35(1):1–9. https://doi.org/10.1007/s11239-012-0752-4
Horiuchi H (2006) Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to problems. Ann Med 38(3):162–172. https://doi.org/10.1080/07853890600640657
Wang TH et al (2006) Aspiring and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27(6):647–654. https://doi.org/10.1093/eurheartj/ehi684
Pozzi N et al (2013) Autoactivation of thrombin precursors. J Biol Chem 288(16):11601–11610. https://doi.org/10.1074/jbc.M113.451542
Lenting PJ et al (1998) The life cycle of coagulation factor VIII in view of its structure and function. Blood 92:3983–3996
Geddings JE (2014) New players in haemostasis and thrombosis. Thromb Haemost 111(4):570–574. https://doi.org/10.1160/TH13-10-0812
Crawley JTB, Lane DA (2008) The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28(2):233–242. https://doi.org/10.1161/ATVBAHA.107.141606
Wood et al (2014) Biology of tissue factor pathway inhibitor. Blood 123(19):2934–2943. https://doi.org/10.1182/blood-2013-11-512764
Castoldi E, Hackeng TM (2008) Regulation of coagulation by protein S. Curr Opin Haematol 15(5):529–536. https://doi.org/10.1097/MOH.0b013e328309ec97
Kalafatis M, Rand MD, Mann KG (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269(50):31869–31880
Rosenberg RD, Damus PS (1973) The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248(18):6490–6505
Lim GB (2015) Anticoagulants. Nat Rev Cardiol. https://doi.org/10.1038/nrcardio.2017.170
Hirsh J et al (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107:1692–1711
Hirsh J et al (2001) Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest J 119(1):64S–94S. doi: 0.1378/chest.119.1_suppl.64S
Basu D et al (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. NEJM 287:324–327. https://doi.org/10.1056/NEJM197208172870703
Salzman EW et al (1975) Management of heparin therapy – controlled prospective trial. NEJM 292:1046–1050. https://doi.org/10.1056/NEJM197505152922002
Pollack CV Jr (2016) Coagulation assessment with the new generation of oral anticoagulants. BMJ 33(6):423–430
Wilson MR, Docherty KF, Gardner RS (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber Drug Rev 27(8):15. https://doi.org/10.1002/psb.1487
Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115(1):15–20. https://doi.org/10.1182/blood-2009-09-241851
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Thielemans, L., Hanif, M., Crawley, J. (2019). The Coagulation Cascade and its Therapeutic Modulation. In: Terracciano, C., Guymer, S. (eds) Heart of the Matter. Learning Materials in Biosciences. Springer, Cham. https://doi.org/10.1007/978-3-030-24219-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-24219-0_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24218-3
Online ISBN: 978-3-030-24219-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)